By Infinium Global Research Aug, 2020
The key factors driving the growth of ophthalmic drugs the market is considered to be increasing geriatric population with rising global population, increase in the prevalence of eye disorders, technological advancement, and increasing awareness of healthcare spending. Moreover, challenges faced by ophthalmic drugs market include the absence of health insurance in developing countries regarding eye diseases and lack of awareness among the people regarding eye diseases and disorders in underdeveloped and developing countries. One of the key opportunities for new entrants is securing drugs through a licensing agreement with major players such as Novartis and Bayer, which could boost their growth over the forecast period.
The report on Global Ophthalmic Drugs Market covers segments such as disease condition and dispenses type. The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The report provides profiles of the companies in the global Abbott Healthcare, Allergan Plc, Johnson & Johnson, Bayer, Valeant Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co., Novartis AG, Renegeron and Santen Pharmaceuticals Company Ltd.